958O Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial

Abstract

g9d2 T-cells function at the crossroad of innate and adaptive antitumor immunity, infiltrate into most tumors, and are MHC-independent killers of tumors. Butyrophilin (BTN) 3A is an immune checkpoint molecule expressed on tumors and immune cells that is part of the stress response that activates g9d2 T-cells. ICT01, an anti-BTN3A mAb targeting all 3 isoforms of BTN3A, induces pAg-independent g9d2 T-cell activation and in vitro/vivo killing of multiple solid and hematologic tumors.